Sign in to view content

The Functional Burden of Diabetic Retinopathy in the United States – How Ranibizumab May Shift Treatment Paradigms

Jeffrey R Willis, MD/PhD

Video
Published 2017

Related

Indirect Comparison of the Relative Effectiveness of Faricimab vs Aflibercept 8 mg in DME and nAMD
Nikolas JS London, MD, FACS, FASRS
Annual Meeting Talks
2025
Baseline DR Severity and Time to DME Resolution in Patients Treated With Ranibizumab in the RIDE and RISE Clinical Trials
Katherine E Talcott, MD
Annual Meeting Talks
2021
Efficacy, Durability, and Safety of Faricimab in DME: 2-Year Results From the Phase 3 YOSEMITE and RHINE Trials
Jennifer I. Lim, MD, FARVO, FASRS
Updates from the Field
2022

Category: Diabetic Retinopathy

See more